home / stock / anip / anip news


ANIP News and Press, ANI Pharmaceuticals Inc. From 03/01/23

Stock Information

Company Name: ANI Pharmaceuticals Inc.
Stock Symbol: ANIP
Market: NASDAQ
Website: anipharmaceuticals.com

Menu

ANIP ANIP Quote ANIP Short ANIP News ANIP Articles ANIP Message Board
Get ANIP Alerts

News, Short Squeeze, Breakout and More Instantly...

ANIP - ANI Pharma draws Buy at Guggenheim on potential of autoimmune therapy

ANI Pharmaceuticals ( NASDAQ: ANIP ) gained ~3% in the morning hours Wednesday, marking the biggest intraday gain since late January, after Guggenheim launched its coverage with a Buy recommendation citing the company’s hormonal autoimmune therapy Cortrophin Gel. Cortrophin...

ANIP - ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023, at 8:30 a.m. ET

ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its fourth quarter and full year 2022 financial results on Thursday, March 9, 2023, prior to market open. Nikhil Lalwani, President and Chief Executive O...

ANIP - 2023 A Big Year For Testosterone: AbbVie And ANI Pharmaceuticals Best Positioned To Benefit

Summary Results from three major testosterone trials expected in 2023, including the largest testosterone cardiovascular safety/efficacy trials for men and women. AbbVie led Androgel 1.62% 5,246-participant cardiovascular safety trial is also measuring efficacy for dysthymia, clinical f...

ANIP - ANI Pharmaceuticals gets FDA approval for generic levocarnitine tablets

ANI Pharmaceuticals ( NASDAQ: ANIP ) on Monday said it had got U.S. Food and Drug Administration (FDA) approval for its generic version of the drug carnitor. The FDA approval was for ANIP's levocarnitine tablets, 330 mg. ANIP's levocarnitine tablets are a generic version of the dr...

ANIP - ANI Pharmaceuticals Announces the FDA Approval and Launch of Levocarnitine Tablets USP

ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Levocarnitine Tablets USP, 330 mg. ANI’s Levocarnitine Tablets are the generic version of ...

ANIP - ANI Pharmaceuticals Announces the FDA Approval and Launch of Fluoxetine Oral Solution USP

ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that the Company received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Fluoxetine Oral Solution, USP 20 mg/5 mL. ANI&...

ANIP - ANI Pharmaceuticals launches generic antibiotic trimethoprim with FDA approval in bag

ANI Pharmaceuticals ( NASDAQ: ANIP ) said the U.S. Food and Drug Administration (FDA) approved its generic antibiotic trimethoprim tablets USP, 100 mg. Trimethoprim is an antibiotic used to treat bacterial infections. "As we continue to focus on bringing niche...

ANIP - ANI Pharmaceuticals Announces the FDA Approval and Launch of Trimethoprim Tablets USP

ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Trimethoprim Tablets USP, 100 mg. ANI’s Trimethoprim Tablets are the generic ver...

ANIP - ANI Pharmaceuticals, Inc. (ANIP) Q3 2022 Earnings Call Transcript

ANI Pharmaceuticals, Inc. (ANIP) Q3 2022 Earnings Conference Call November 09, 2022, 08:00 AM ET Company Participants Judy DiClemente - IR Nikhil Lalwani - President and CEO Steve Carey - CFO Christopher Mutz - Head, Rare Disease Conference Call Partici...

ANIP - ANI Pharmaceuticals reports Q3 earnings miss; reaffirms FY22 guidance

ANI Pharmaceuticals press release ( NASDAQ: ANIP ): Q3 Non-GAAP EPS of $0.64 beats by $0.09 . Revenue of $83.8M (+61.0% Y/Y) beats by $5.44M . Adjusted non-GAAP EBITDA of $19.6M. Reiterates total Company net revenue guidance of $295 million to $315 million ...

Previous 10 Next 10